Clinical status and optimal use of rituximab for B-cell lymphomas

Rituximab (IDEC-C2B8 [Rituxan]) is a chimeric anti-CD20 monoclonal antibody (MoAb) that was recently approved by the FDA for the treatment of patients with low-grade or follicular B-cell non-Hodgkin's lymphoma. Its potential efficacy in other B-cell malignancies is currently being explored. This article reviews the mechanisms of action of rituximab, as well as preclinical data and results of the clinical trials that led to ifs approval. Also discussed are the mechanics of administering rituximab on the recommended weekly x 4 outpatient schedule. Finally, the article describes ongoing and planned trials of rituximab irt other dosage schedules, in other B-cell neoplasms, and in conjunction with chemotherapy. As the first MoAb to gain FDA approval for the treatment of a malignancy, rituximab signals the beginning of a promising newer a in cancer therapy.